

induction of programmed cell death. Particular peptides found to be capable of inducing programmed cell death include a sequence of human eIF4G<sub>569-580</sub>, wheat eIF4G<sub>62-73</sub> and human eIF4E-BP(1&2)<sub>51-62</sub> and derivatives and fragments thereof. Numbering according to Accession numbers AF104913, M95746, NM\_004095 and NM\_004096 respectively.

Thus the peptides of use in the present invention include the sequences;

human eIF4G<sub>569-580</sub>, KKRYDREFLLGF [SEQ ID NO: 1]  
 10 wheat eIF4G<sub>62-73</sub> RVRYSRDQLLDL [SEQ ID NO: 2] and,  
 human eIF4E-BP(1&2)<sub>51-60</sub> RIIYDRKFL(L/M) [SEQ ID NO: 3], and  
 variants or derivatives thereof. A consensus may be derived from the above three sequences.

Thus, in a further aspect the present invention provides use of a peptide comprising a sequence:

YxxxxLØ [SEQ ID NO: 4]

wherein x is a variable amino acid and Ø is Leu, Met or Phe;

or a fragment or derivative thereof in therapy, more particularly for the induction of programmed cell death.

Alternatively the peptide may comprise the sequence:

(K/R)xxYxxx(F/Q)L(L/M) [SEQ ID NO: 5]

It is to be understood that "K/R" refers to an amino acid which is either lysine (K) or arginine (R), "x" may be any of the 20 amino acids or may be a synthetic or unnatural amino acid, "F/Q" refers to an amino acid which is either phenylalanine (F) or glutamine (Q) and "L/M" refers to an amino acid which is either leucine (L) or

methionine (M). The remainder of the sequence is understood to relate to the standard single letter symbol for amino acids.

Particular sequences may include

- 5 KKRYDREFLLGF [SEQ ID NO: 1] (human eIF4G<sub>413-424</sub>),  
RVRYSRDQLLDL [SEQ ID NO: 2] (wheat eIF4G<sub>62-73</sub>) and  
RIIYDRKFL(L/M) [SEQ ID NO: 3] (human eIF4E-BP<sub>51-60</sub>).

The invention also relates to the use of fragments and derivatives of these peptides. Fragments are defined  
10 herein as any portion of the peptides described that substantially retain the activity of the parent peptide. Derivatives are defined as any modified forms of said peptides which also substantially retain the activity of the parent peptide. Such derivatives may take the form of  
15 amino acid substitutions which may be in the form of like for like eg. a polar amino acid residue for another polar residue or like for non-like eg. substitution of a polar amino acid residue for a non-polar residue as discussed in more detail below.

20 Thus, the present invention further provides derivatives of the sequences disclosed above for use in the induction of cell death.

Replacement amino acid residues may be selected from the residues of alanine, arginine, asparagine, aspartic  
25 acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. The replacement amino acid residue

and homologous and non-homologous substitution is defined using these classes. Thus, homologous substitution is used to refer to substitution from within the same class, whereas non-homologous substitution refers to substitution  
5 from a different class or by an unnatural amino acid.

In general, the term "peptide" refers to a molecular chain of amino acids with the defined biological activity. If required, it may be modified *in vivo* and/or *in vitro*, for example, by glycosylation, myristoylation, amidation,  
10 carboxylation or phosphorylation. Thus *inter alia* peptides, oligopeptides and polypeptides are included. The peptides disclosed herein may be obtained, for example, by synthetic or recombinant techniques known in the art.

The term also extends to cover, for example,  
15 polypeptides which contain any of the above disclosed sequences and, in particular, wherein biological activity, that is, the polypeptide is capable of binding to eIF4E protein, is retained. Typically the length of the peptides of the present invention are between 7 - 25 amino acids in  
20 length, more preferably 10 - 20 amino acids in length.

In a further aspect the present invention provides use of a peptide comprising sequence:  
YxxxxLØ [SEQ ID NO: 4] wherein x is a variable amino acid and Ø is Leu, Met or Phe;  
25 or fragment or derivate thereof in the manufacture of a medicament for therapy, more particularly for inducing cell death.

In particular, the peptide is used to induce the cell death in tumour cells.

In yet a further aspect, the present invention provides a polynucleotide fragment encoding a peptide  
5 comprising sequence:

YxxxxLØ [SEQ ID NO: 4] wherein x is a variable amino acid and Ø is Leu, Met or Phe.

"Polynucleotide fragment" as used herein refers to polymeric form of nucleotides of any length, both to  
10 ribonucleic acid sequence and to deoxyribonucleic acid sequences. In principal, this term refers to the primary structure of the molecule, thus this term includes double stranded and single stranded DNA, as well as double and single stranded RNA, and modifications thereof.

15 As described above, the presence of a peptide comprising the above sequences can induce programmed cell death (apoptosis) in mammalian cells. The peptides of the present invention therefore have utility in treating diseases associated with undesirable cell  
20 proliferation/neoplasia. In particular the peptides have utility as anticancer or antitumour agents. Therefore, it may be desirable to direct the peptides to the site of action ie. the tumour. Thus, in the case of peptides, they may be conjugated to or associated with cell and/or tumour  
25 targeting agents, or in the case of the polynucleotide fragments provided as an expression cassette which comprises a polynucleotide sequence which encodes any of the above disclosed peptides, and a tumour-specific

elevated translation of growth related mRNAs, which are normally translationally repressed (19). In order to study directly the role of eIF4E in cell transformation, a series of experiments were carried out.

5 Human eIF4G<sub>(413-424)</sub> was conjugated to Penetratin, a known cell membrane translocation peptide of sequence RQIKIWFQNRRMKWKK [SEQ ID NO: 6] (see patent EP485578). Description of its synthesis and coupling to other peptides may be found in US Patent 5,888,762. The human eIF4G<sub>(413-</sub>  
10 <sub>424)</sub>-Penetratin conjugate was found to bind recombinant human eIF4E *in vitro* (see Figure 4). Surprisingly, wheat eIF4E<sub>(62-73)</sub> bound to and pulled down more recombinant human eIF4F *in vitro* than human eIF4G<sub>(569-580)</sub> did (see Figure 5). It was also observed that recombinant human 4E-BP1 competed with  
15 either human eIF4G<sub>(569-580)</sub> or wheat eIF4G<sub>(62-73)</sub> for binding of recombinant human eIF4E *in vitro* (see Figure 6).

Wheat eIF4G<sub>(62-73)</sub> was found to inhibit cap-dependent translation initiation, but not cap-independent translation initiation *in vitro* (see Figure 7). However, inhibition of  
20 cap dependent translation by eIF4G peptides was not detected in cultured mammalian cells. Furthermore, no inhibition of general translation by peptides from eIF4G or 4E-BP was detected in cultured mammalian cells.

Human eIF4G<sub>(569-580)</sub>-Penetratin exhibited a cytotoxic or  
25 cytostatic effect on selected cell lines (HaCaT cells, no effect observed with short treatment (<24h with 20µM) but treatment of 60h serum starved cells began to die within 15 minutes of peptide treatment. Furthermore, human eIF4G<sub>(413-</sub>